-
Susceptibility Genes for Antipsychotic-induced Extrapyramidal Symptoms as Modifier Genes in Parkinson's Disease and L-dopa Treatment Response
… to LID. DNA and clinical data have been collected from Jewish PD patients in Israel, and from Italian patients. In addition, we will use neuroimaging data from DAT-scans to evaluate the role of these genes in …
-
Development of an MRI-based Imaging Biomarker for the Detection of Alpha-Synuclein in Parkinson's disease
… the patient. To accomplish both these goals, a fragment from an antibody that detects alpha-synuclein will be linked … currently no accurate way to diagnose Parkinson’s disease from MRI imaging. Although some biomarkers for Parkinson’s … accessibility to diagnosis for patients who live far from clinical centers. Further, although research has shown …
-
Inhibition of LINGO-1 as a Novel Target for Regeneration in Pre-clinical PD Models
… application of LINGO-1 inhibitors prevents dopamine neurons from dying in pre-clinical models of PD caused by oxidative … capacity of LINGO-1 inhibition to protect dopamine neurons from degeneration in a pre-clinical model of … that inhibition of LINGO-1 will protect dopamine neurons from alpha-synuclein-mediated neuronal damage and …
-
Native Alpha-Synuclein Oligomers in Living Cells: Relevance for Diagnosing and Treating Parkinson’s Disease
… and induced pluripotent stem cell-derived neurons from PD patients versus from healthy individuals. Relevance to Diagnosis/Treatment … how alpha-synuclein in cells of PD subjects differs from that in cells of healthy individuals, we aim to …
-
Ghrelin Agonist as a Novel Therapeutic Approach to Alleviate Gut Dysmotility and Levodopa-inhibited Gastric Emptying in PD Models
… (PD) have altered progression of ingested aliments/liquid from their stomach to the intestine, as well as suffer from constipation, and there is no efficient remedy to … assess the time taken by a viscous solution to be emptied from the stomach under those conditions with simultaneous …
-
Amelioration of Mitochondrial Oxidant Stress by Isradipine and Rasagiline
… therapy in PD. This conclusion is consistent with data from the Phase II clinical trial with isradipine in which a … strategies will be used to move monoamine oxidase away from mitochondria to determine whether their positioning is … in pre-clinical and human models (dopamine neurons derived from induced pluripotent stem cells) to maximize their …